SYN1
Synapsin-1
Also known as: MRX50, SYN1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17600
- Gene
- SYN1
- Ensembl
- ENSG00000008056
- Chromosome
- X
- Canonical length
- 705 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene is a member of the synapsin gene family. Synapsins encode neuronal phosphoproteins which associate with the cytoplasmic surface of synaptic vesicles. Family members are characterized by common protein domains, and they are implicated in synaptogenesis and the modulation of neurotransmitter release, suggesting a potential role in several neuropsychiatric diseases. This member of the synapsin family plays a role in regulation of axonogenesis and synaptogenesis. The protein encoded serves as a substrate for several different protein kinases and phosphorylation may function in the regulation of this protein in the nerve terminal. Mutations in this gene may be associated with X-linked disorders with primary neuronal degeneration such as Rett syndrome. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
705 residues, UniProt reviewed canonical sequence.
>P17600|SYN1
1 MNYLRRRLSD SNFMANLPNG YMTDLQRPQP PPPPPGAHSP GATPGPGTAT AERSSGVAPA
61 ASPAAPSPGS SGGGGFFSSL SNAVKQTTAA AAATFSEQVG GGSGGAGRGG AASRVLLVID
121 EPHTDWAKYF KGKKIHGEID IKVEQAEFSD LNLVAHANGG FSVDMEVLRN GVKVVRSLKP
181 DFVLIRQHAF SMARNGDYRS LVIGLQYAGI PSVNSLHSVY NFCDKPWVFA QMVRLHKKLG
241 TEEFPLIDQT FYPNHKEMLS STTYPVVVKM GHAHSGMGKV KVDNQHDFQD IASVVALTKT
301 YATAEPFIDA KYDVRVQKIG QNYKAYMRTS VSGNWKTNTG SAMLEQIAMS DRYKLWVDTC
361 SEIFGGLDIC AVEALHGKDG RDHIIEVVGS SMPLIGDHQD EDKQLIVELV VNKMAQALPR
421 QRQRDASPGR GSHGQTPSPG ALPLGRQTSQ QPAGPPAQQR PPPQGGPPQP GPGPQRQGPP
481 LQQRPPPQGQ QHLSGLGPPA GSPLPQRLPS PTSAPQQPAS QAAPPTQGQG RQSRPVAGGP
541 GAPPAARPPA SPSPQRQAGP PQATRQTSVS GPAPPKASGA PPGGQQRQGP PQKPPGPAGP
601 TRQASQAGPV PRTGPPTTQQ PRPSGPGPAG RPKPQLAQKP SQDVPPPATA AAGGPPHPQL
661 NKSQSLTNAF NLPEPAPPRP SLSQDEVKAE TIRSLRKSFA SLFSDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SYN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.52
- Highest tissue expression
- 312 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 312 nTPM
- cerebellum: 170 nTPM
- hippocampal formation: 167 nTPM
- amygdala: 154 nTPM
- hypothalamus: 126 nTPM
- basal ganglia: 107 nTPM
Single-cell type
- brain excitatory neurons: 58 nCPM
- brain inhibitory neurons: 52 nCPM
- other brain neurons: 52 nCPM
- retinal amacrine cells: 17 nCPM
- retinal bipolar cells: 15 nCPM
- pancreatic islet cells: 15 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 724 nTPM
- white matter: 468 nTPM
- basal ganglia: 352 nTPM
- hippocampal formation: 333 nTPM
- amygdala: 270 nTPM
- hypothalamus: 228 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SYN1.
Disease | AllUniProt
Conditions SYN1 is implicated in, by any mechanism.
- Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders (EPILX1) MIM:300491
- Intellectual developmental disorder, X-linked 50 (XLID50) MIM:300115
Disease | GeneticClinVar
66 pathogenic / likely-pathogenic of 663 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders
- Intellectual disability, X-linked 50
- SYN1-related disorder
- Inborn genetic diseases
- Seizure
ReferencesPubMed · IEDB
Publications for SYN1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Maternal synapsin autoantibodies are associated with neurodevelopmental delay.
2023 · Front Immunol · RCR 0.7 · 6 citations - Synapsin autoantibodies during pregnancy are associated with fetal abnormalities.
2023 · Brain Behav Immun Health · RCR 0.6 · 6 citations - Synapsin I identified as a novel brain-specific autoantigen.
2001 · J Investig Med · RCR 0.3 · 10 citations - Epitope specificity of anti-synapsin autoantibodies: Differential targeting of synapsin I domains.
2018 · PLoS One · RCR 0.2 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.25
- gnomAD pLI
- 0.99
- gnomAD missense Z
- 2.97
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- chemical synaptic transmission
- neuron development
- neurotransmitter secretion
- regulation of neurotransmitter secretion
- regulation of synaptic vesicle cycle
- regulation of synaptic vesicle exocytosis
- synapse organization
- synaptic vesicle clustering
Molecular functions
- actin binding
- ATP binding
- calcium-dependent protein binding
- cytoskeletal protein-membrane anchor activity
- identical protein binding
- protein kinase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SYN1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SYN1 as an antibody target. Whether an autoantibody or antibody against SYN1 could matter depends on whether native SYN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SYN1 is annotated at the cell surface, where native SYN1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SYN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...